AC
ICPT

AXQ Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

AXQ Capital’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,341
Closed -$153K – 673
2022
Q4 		$153K Buy
+12,341
New +$175K 0.11% 283

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

AXQ Capital's ICPT Position: Q1 2023 in Review

AXQ Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2023, closing a stake of 12,341 shares — an estimated $153K sold.

AXQ Capital first reported a position in ICPT in Q4 2022 and held it in 1 quarter. The position peaked at $153K in Q4 2022. 144 funds tracked by Wall St. Rank hold ICPT as of Q1 2023.

  • AXQ Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • AXQ Capital sold 12,341 Intercept Pharmaceuticals, Inc. shares in Q1 2023, an estimated $153K.
  • AXQ Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2022 and held it in 1 quarter.
  • AXQ Capital's Intercept Pharmaceuticals, Inc. position peaked at $153K in Q4 2022.
  • 144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2023.

Based on AXQ Capital's 13F filing for Q1 2023, filed 10 May 2023.